Replies to post #590289 on NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

You won’t receive a response to this and you know why!

[flipper44]

You must also remember, that is a combination trial as well, wherein poly-iclc was tested in a precursor trial in an Orphan disease with DCVax-l, and, now, in the current trial, the PD1 inhibitor (likely Keytruda),added in the trial we are discussing, is already used against many cancers, with DCVax-l, the additional part of the combo, likely to receive separate approval as well from its phase iii trial. Dr. Pazdur himself has stated in general, therapies that are making incredible survival breakthroughs in rare diseases will not be ignored by the FDA. I’m sure that current trial is being watched very very closely. Do not forget, we are entering the age of real world evidence wherein something like this might be a candidate for a rwd trial upon any marketing. As CaptainO recently stated, “the numbers are too good” to ignore.

[ATLnsider]

Yes, the maturation and activation agents can be changed at NWBio’s discretion depending on what type of cancer, tumor type, tumor location, etc. It is still DCVax-L.

What makes it DCVax-L is:

1. It uses each patients own tumor tissue & dendritc cells.

2. It uses a maturation agent(s) (of NWBio’s choosing from the list of maturation agents on NWBio’s process patents).

2. It uses an activation agent(s) (of NWBio’s choosing from the list of activation agents on NWBio’s process patents).

NWBio has basically gone from a 13% overall survival rate, up to a 50%+ overall survival rate for DCVax-L, without the shorts even noticing. But, that is a “them problem”. :-)